An experimental cholesterol fighter being developed by Alnylam Pharmaceuticals and The Medicines Co slashed levels of bad LDL cholesterol and remained effective for six months, according to data from a […]
Merck cholesterol drug’s odds dim after Lilly failure
"Bad" LDL Cholesterol, "Good" LDL Cholesterol, Analysts, Cardiologists, Cholesterol, Cholesteryl Ester Transfer Protein (CETP) Inhibitor, Clinical Trials, Health, Healthcare, Heart Attacks, Heart Attacks, Outcomes Data, PCSK9 inhibitors, Potential Blockbusters, R&D, Shares, Shares, Stroke, Studies, Therapeutics, Wall StreetThe odds that Merck & Co’s high-stakes cholesterol drug will succeed have dropped dramatically after Eli Lilly and Co said its similar medicine failed to reduce heart attacks and strokes, […]